AR093126A1 - Formulaciones de liberacion modificada para oprozomib - Google Patents
Formulaciones de liberacion modificada para oprozomibInfo
- Publication number
- AR093126A1 AR093126A1 ARP130103868A ARP130103868A AR093126A1 AR 093126 A1 AR093126 A1 AR 093126A1 AR P130103868 A ARP130103868 A AR P130103868A AR P130103868 A ARP130103868 A AR P130103868A AR 093126 A1 AR093126 A1 AR 093126A1
- Authority
- AR
- Argentina
- Prior art keywords
- oprozomib
- release formulations
- modified release
- pharmaceutically acceptable
- hplc
- Prior art date
Links
- 108010064641 ONX 0912 Proteins 0.000 title abstract 3
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title abstract 3
- 229950005750 oprozomib Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093126A1 true AR093126A1 (es) | 2015-05-20 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103868A AR093126A1 (es) | 2012-10-24 | 2013-10-24 | Formulaciones de liberacion modificada para oprozomib |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (enExample) |
| EP (1) | EP2912025A4 (enExample) |
| JP (1) | JP6505604B2 (enExample) |
| KR (1) | KR20150070406A (enExample) |
| CN (1) | CN104968650A (enExample) |
| AP (1) | AP3681A (enExample) |
| AR (1) | AR093126A1 (enExample) |
| AU (1) | AU2013334258A1 (enExample) |
| BR (1) | BR112015008572A2 (enExample) |
| CA (1) | CA2888039A1 (enExample) |
| CL (1) | CL2015001085A1 (enExample) |
| CR (1) | CR20150266A (enExample) |
| EA (1) | EA201590797A1 (enExample) |
| HK (2) | HK1208222A1 (enExample) |
| IL (1) | IL238244A0 (enExample) |
| IN (1) | IN2015DN03921A (enExample) |
| MX (1) | MX2015005069A (enExample) |
| PE (1) | PE20151051A1 (enExample) |
| PH (1) | PH12015500823A1 (enExample) |
| SG (1) | SG11201502849XA (enExample) |
| TN (1) | TN2015000135A1 (enExample) |
| TW (1) | TW201422255A (enExample) |
| UY (1) | UY35091A (enExample) |
| WO (1) | WO2014066681A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| WO2018005781A1 (en) | 2016-06-29 | 2018-01-04 | Kezar Life Sciences | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof |
| US20180078532A1 (en) * | 2016-09-21 | 2018-03-22 | Amgen Inc. | Immediate release formulations for oprozomib |
| WO2018112078A1 (en) | 2016-12-14 | 2018-06-21 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| BR112020005079A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| EA011451B1 (ru) * | 2001-02-12 | 2009-04-28 | Уайт | Новая соль сукцинат о-десметилвенлафаксина |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| EP2623113B1 (en) * | 2005-11-09 | 2017-05-31 | Onyx Therapeutics, Inc. | Compound for enzyme inhibition |
| US20100172988A1 (en) * | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CA2701778C (en) * | 2007-10-04 | 2018-09-11 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| AR075899A1 (es) * | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
-
2013
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en not_active Ceased
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2912025A4 (en) | 2016-06-08 |
| PH12015500823A1 (en) | 2015-06-22 |
| WO2014066681A1 (en) | 2014-05-01 |
| JP2015535255A (ja) | 2015-12-10 |
| TN2015000135A1 (en) | 2016-10-03 |
| US9295708B2 (en) | 2016-03-29 |
| EA201590797A1 (ru) | 2016-02-29 |
| PE20151051A1 (es) | 2015-08-03 |
| TW201422255A (zh) | 2014-06-16 |
| CN104968650A (zh) | 2015-10-07 |
| SG11201502849XA (en) | 2015-05-28 |
| BR112015008572A2 (pt) | 2017-07-04 |
| KR20150070406A (ko) | 2015-06-24 |
| EP2912025A1 (en) | 2015-09-02 |
| CA2888039A1 (en) | 2014-05-01 |
| JP6505604B2 (ja) | 2019-04-24 |
| AU2013334258A1 (en) | 2015-04-30 |
| CR20150266A (es) | 2015-08-14 |
| MX2015005069A (es) | 2015-07-17 |
| IN2015DN03921A (enExample) | 2015-10-02 |
| IL238244A0 (en) | 2015-06-30 |
| UY35091A (es) | 2014-05-30 |
| HK1215709A1 (zh) | 2016-09-09 |
| US20140113855A1 (en) | 2014-04-24 |
| US20160213610A1 (en) | 2016-07-28 |
| AP2015008387A0 (en) | 2015-04-30 |
| AP3681A (en) | 2016-04-19 |
| HK1208222A1 (en) | 2016-02-26 |
| CL2015001085A1 (es) | 2015-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21072161A (es) | Composiciones de liberación retardada de linaclotida | |
| CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| DOP2014000204A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| DOP2013000239A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso. | |
| CO7121351A2 (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
| MX376122B (es) | Composiciones de plinabulina. | |
| DOP2011000382A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas | |
| MX2011010415A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| BR112012033755A2 (pt) | composições e métodos antissépticos estáveis | |
| UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| DOP2016000253A (es) | Nuevos compuestos | |
| PE20151979A1 (es) | Compuestos quimicos | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| MX340983B (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| MX2015016971A (es) | Formulacion que comprende un agente hipolipidemico. | |
| BR112014014877A2 (pt) | derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| CR20130318A (es) | Nuevos compuestos de benzodioxol-piperazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |